Once again, DAPT proven to cause more harm than good
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
Preprocedural dual antiplatelet therapy (DAPT) before transfemoral transcatheter aortic valve implantation (TF-TAVI) leads to a higher incidence of bleeding with no clinical benefit of reduce thrombotic events compared with either preprocedural single antiplatelet therapy (SAPT) or no antiplatelet therapy (APT) at all.
A retrospective analysis of a prospective, multicenter, observational, cohort registry.
540 patients (median age, 85 y; 68.1% female) underwent TF-TAVI between October 2013 and July 2015.
167 patients received preprocedural SAPT, 293 patients received preprocedural DAPT, and 80 patients had no preprocedural APT.
Funding: Source of funding not disclosed.
Overall, 31.4% experienced bleeding, 28.9% required transfusions, 1.7% died, 2.6% experienced stroke, and 0.6% had myocardial infarction.
No incidence of thrombosis in total cohort.
Bleeding was significantly higher in patients on DAPT compared to no pre TAVI APT and SAPT groups (36.5% vs 25.5%; P=.006).